Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial -

Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial
Information type: Randomised controlled trials
Source: JAMA Internal Medicine
Specialities: Infection and infectious diseases
Summary
Among 124 patients in the study, fewer patients on antivirals had viral reactivation in the blood (12 patients in the control group, vs 1 in the valganciclovir group and 2 in the valacyclovir group (combined treatment groups vs control: HR 0.14; 95% CI 0.04-0.50).
UKMi comment
The valacyclovir arm was halted prematurely because of higher mortality; 14 of 34 patients (41.2%) had died by 28 days, compared with 5 of 37 (13.5%) patients in the control arm at the point of the decision to halt this arm.
Related links: